FDA Updates Safety Labelling for Capecitabine and 5-FU on Risks Associated with DPD Deficiency By Ogkologos - February 18, 2026 321 0 Facebook Twitter Google+ Pinterest WhatsApp Patients should be tested for genetic variants of DPYD prior to initiating treatment Source RELATED ARTICLESMORE FROM AUTHOR Perioperative Durvalumab Plus FLOT Improves OS in Patients with Resectable Gastric or GEJ Adenocarcinoma Advancing Childhood Cancer Research: A Conversation with Dr. Brigitte Widemann Azacitidine-Venetoclax Prolongs EFS Over Induction Chemotherapy Among Induction-Eligible Patients with AML MOST POPULAR What’s happened to cancer clinical trials during the COVID-19 pandemic? November 4, 2020 Study Explores Jaw Problem Linked to Zoledronic Acid, Finds Risk Factors January 28, 2021 Imetelstat Shows Durable Transfusion Independence and Disease-Modifying Activity in Heavily Transfused... December 11, 2023 Prostate Cancer December 9, 2019 Load more HOT NEWS One Family’s Mission to Stop Hair Loss from Chemotherapy: Your Stories... Trial Examines Value of Lymph Node Surgery in Advanced Ovarian Cancer Saving Time for Patients and Improving Well-Being Through Mindfulness and Fitness:... Reunión anual de la American Society of Clinical Oncology (ASCO) de...
